IN8bio, Inc. Share Price
NASDAQ: INAB | Micro CapIN8bio, Inc. Stock Performance
Open $1.03 | Prev. Close $0.98 | Circuit Range N/A |
Day Range $1.03 - $1.03 | Year Range $0.90 - $2.71 | Volume 300 |
Average Traded $1.03 |
IN8bio, Inc. Share Price Today
As of 29 August 2026, IN8bio, Inc.'s share price is $1.03. The stock opened at $1.03, compared to its previous close of $0.98. During today's trading session, IN8bio, Inc.'s share price traded between $1.03 and $1.03, with an average price of $1.03. Over the past 52 weeks, the stock has recorded a high of $2.71 and a low of $0.90. In terms of performance, IN8bio, Inc.'s share price has declined by 39.30% over the last six months and is down 52.74% on a year-on-year basis.
IN8bio, Inc. Share Price Chart
IN8bio, Inc. Stock Fundamentals & Key Indicators
Market Cap $4.53M | PE Ratio (TTM) -0.23 | Dividend Yield N/A |
EPS (TTM) $-4.44 | Revenue (TTM) N/A | Return On Equity (TTM) -70.54% |
Profit Margin N/A | Debt to Equity 0.17 | Quarterly Earnings Growth YoY 45.61% |
IN8bio, Inc. Quarterly Profit & Loss
All figures in USD
IN8bio, Inc. Annual Profit & Loss
All figures in USD
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
IN8bio, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.95 | $0.98 | -15.52% |
Jul 2026 | $1.43 | $1.16 | -18.60% |
Jun 2026 | $1.80 | $1.43 | -23.80% |
May 2026 | $1.50 | $1.87 | +26.35% |
Apr 2026 | $1.40 | $1.48 | +1.37% |
Mar 2026 | $1.73 | $1.46 | -14.37% |
Feb 2026 | $1.94 | $1.71 | -13.45% |
Jan 2026 | $2.32 | $1.97 | -15.81% |
Dec 2025 | $2.06 | $2.34 | +16.48% |
Nov 2025 | $1.86 | $2.01 | +4.09% |
Oct 2025 | $2.25 | $1.93 | -10.65% |
Sep 2025 | $2.19 | $2.16 | -1.37% |
INAB Share Price FAQs
What is IN8bio, Inc. share price today?
What is the 52 week high and 52 week low of IN8bio, Inc. stock?
What is INAB's market capitalisation today?
What is INAB's net income for the last quarter?
What is the 5 year returns of INAB?
What is the high & low stock price of INAB today?
Can I buy INAB shares in India?